Evidence map›Paper›PMID 42031428›Full record

ArticleJournal for immunotherapy of cancer2026

Rapid response: Context-dependent immunomodulatory effects of JAK inhibition in the management of severe immune-related adverse events.

Lingrong Tang, Wenbin Mo, Nan Li, Guangwei Tian

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lingrong TangDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0001-6446-7345
Wenbin MoDepartment of Hematology, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0002-4030-256X
Nan LiDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0002-6855-4910
Guangwei TianDepartment of Radiation Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China tgwcmu8901@126.com.ORCID http://orcid.org/0000-0002-3470-4925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have indicated that Janus kinase inhibitors (JAKi) exert context-dependent immunomodulatory effects in cancer immunotherapy. In this rapid response, we comment on the prospective cohort study by Habib

Indexed as

Immune Checkpoint InhibitorsImmunotherapyJanus Kinase InhibitorsNeoplasmsHumansImmunomodulationImmune Checkpoint InhibitorsJanus Kinase InhibitorsImmune Checkpoint InhibitorImmune related adverse event - irAEJAK-STAT

Identifiers

PMID42031428
PMCPMC13110670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.